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BACKGROUND: Whether biochemical recurrence (BR) is a significant predictive factor of mortality after definitive radiation therapy
for prostate cancer remains unknown. The aim of the current study was to investigate the relation between BR and overall mortality
(OAM) in high-risk prostate cancer patients who were treated with carbon-ion radiotherapy (CIRT) and had long-term follow-up in 2
prospective trials. METHODS: In the 2 phase 2 clinical trials, which involved 466 prostate cancer patients who received 63.0 to 66.0
Gy of CIRT (relative biological effect) in 20 fractions between 2000 and 2007, 324 patients who were deemed to be at high risk on
the basis of the modified D’Amico classification criteria and received CIRT along with androgen-deprivation therapy (ADT) were
examined. The OAM rate was adjusted for the ADT duration, and multivariate analyses using a Cox proportional hazards model were
performed for OAM with BR as a time-dependent covariate. RESULTS: The median follow-up period was 107.4 months, and the 5-
and 10-year OAM rates after adjustments for the ADT duration were 7.0% (95% confidence interval [CI], 4.0%-9.4%) and 23.9% (95%
CI, 16.4%-26.2%), respectively. A multivariate analysis revealed that the presence of BR (hazard ratio, 2.82; 95% Cl, 1.57-5.08; P 5 .001)
was one of the predictive factors for OAM. On the other hand, the duration of ADT had no impact on OAM. CONCLUSIONS: BR after
CIRT combined with ADT is an independent predictive factor for OAM in high-risk prostate cancer patients. The results of this study
could be applied to other high-dose radiation therapies. Cancer 2016;122:3225-31. VC 2016 The Authors. Cancer published by Wiley
Periodicals, Inc. on behalf of American Cancer Society. This is an open access article under the terms of the Creative Commons Attri-
bution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly
cited, the use is non-commercial and no modifications or adaptations are made.
KEYWORDS: biochemical recurrence, carbon-ion radiotherapy, high-risk prostate cancer, mortality, Phoenix definition, prostate-spe-
cific antigen (PSA), prostate-specific antigen failure.
INTRODUCTION
Radiotherapy (RT) and prostatectomy have played important roles in the radical treatment of patients with localized pros-
tate cancer.1 In both treatments, the prostate-specific antigen (PSA) level is central to prostate cancer management. Before
treatment, according to the National Comprehensive Cancer Network1 and the D’Amico classification,2 the PSA level is
regarded as an important risk factor along with the T stage and the Gleason score (GS). After treatment, an increase in the
PSA level suggests very early-stage tumor recurrence, which is known as biochemical recurrence (BR).3 An increase in the
PSA level exceeding 0.2 ng/mL after prostatectomy or an increase of 2.0 ng/mL from the nadir after RT is generally
accepted as the standard definition of BR.4,5 Because prostate cancer generally has a long natural history and salvage ther-
apy, including androgen-deprivation therapy (ADT), and chemotherapy are effective for patients after BR,1 long-term
survival after BR is anticipated for many of these patients.6 However, it is not known whether BR is truly useful as a
Corresponding author: Hiroshi Tsuji, MD, PhD, Research Center Hospital for Charged Particle Therapy, National Institute of Radiological Sciences, 4-9-1 Anagawa,
Inage-Ku, Chiba City, 263-8555 Japan; Fax: (011) 81-43-284-0198; h_tsuji@nirs.go.jp
1Research Center Hospital for Charged Particle Therapy, National Institute of Radiological Sciences, Chiba, Japan; 2Department of Radiation Oncology, Graduate
School of Medicine, Tsukuba University Faculty of Medicine, Ibaraki, Japan; 3Kanagawa Cancer Center, Yokohama, Japan; 4Department of Urology, Japan Commu-
nity Health Care Organization Tokyo Shinjuku Medical Center, Tokyo, Japan; 5Department of Urology, Toho University Sakura Medical Center, Chiba, Japan;
6Department of Urology, Graduate School of Medicine, Chiba University, Chiba, Japan; 7Department of Public Health, Dokkyo Medical University School of Medi-
cine, Tochigi, Japan
We deeply appreciate Daniel K. Ebner for his advice and proofreading of the manuscript.
DOI: 10.1002/cncr.30050, Received: February 5, 2016; Revised: March 18, 2016; Accepted: April 4, 2016, Published online June 28, 2016 in Wiley Online Library
(wileyonlinelibrary.com)
Cancer October 15, 2016 3225
Original Article
predictive factor for mortality after radical surgery and RT
for prostate cancer.7,8 In fact, previous studies have found
that the time interval to BR and the PSA doubling time
have a significant relation with mortality after recur-
rence,9-14 but there is little evidence that BR itself has an
impact on mortality.
The National Institute of Radiological Sciences
(NIRS) in Chiba, Japan, started carbon-ion radiotherapy
(CIRT) in 1994 and began treatments for localized pros-
tate cancer in 1995. After 2 phase 1/2 dose-escalation tri-
als, 2 phase 2 fixed dose clinical trials were performed
from April 2000 through August 2007.15,16 CIRT has a
potential clinical benefit because of its better dose distri-
bution and greater biological effects in comparison with
RT using photons.17,18 Several favorable treatment out-
comes have been reported, especially for high-risk prostate
cancer patients who received CIRT combined with
ADT.19,20 However, our previous study demonstrated
that prostate cancer–specific mortality (PCSM) was
observed only in the high-risk group, even when CIRT
was administered.21
To date, the relation between BR and mortality after
CIRT has not been evaluated, so the purpose of this study
was to investigate the impact of BR on overall mortality
(OAM) or PCSM in patients with high-risk prostate can-
cer (according to the modified D’Amico classification) af-
ter CIRT.
MATERIALS AND METHODS
Between April 2000 and August 2007, 2 prospective clini-
cal trials—9904 (66.0 Gy [relative biological effect
(RBE)] over 20 fractions, April 2000 to July 2005) and
9904-(2) (63 Gy [RBE] over 20 fractions, September
2005 to August 2007)—were conducted, and they
involved 466 patients with clinically localized prostate
cancer treated at the NIRS. The eligibility criteria for the
2 protocols were noted in previous reports.16,19-21 In sum-
mary, tumors were verified as adenocarcinomas and classi-
fied as T1-T3N0M0. The T stage was evaluated
according to TNM Classification of Malignant Tumours
(seventh edition),22 and staging was determined by digital
rectal examination, ultrasonography, pelvic computed to-
mography (CT), magnetic resonance imaging, and iso-
tope bone scanning. The GS was determined with an
assessment of the central pathology of all tumors before
treatment was started. Exclusion criteria were previous
irradiation to the pelvis, a performance status of 3 or 4,
the presence of other malignant cancers, and previous
treatment of the cancer other than ADT for less than 6
months. All patients signed an informed consent form,
and this study was approved by the institutional ethics
committee.
At the NIRS, the definition of the high-risk prostate
cancer group is slightly different from standard risk classi-
fications such as the National Comprehensive Cancer
Network and D’Amico classifications.1,2 The high-risk
group in this study was determined according to a modi-
fied version of the D’Amico classification and was defined
as follows: T2c/T3 disease, GS 8, or PSA level> 20 ng/
mL.
In general, ADT was administered as a combination
of anti-androgen therapy by oral administration and a
luteinizing hormone-releasing hormone analogue by sub-
cutaneous injection. Neoadjuvant and concomitant ADT
was applied for 2 to 6 months for all patients, with adju-
vant ADT generally administered for at least 2 years,
except in T2cN0M0 patients with a PSA level  20 ng/
mL and a GS 7, for whom adjuvant ADT was adminis-
tered for no more than 6 months.
The radiation dose was expressed in grays (RBE)
(physical carbon ion [Gy] 3 RBE).18 The RBE value for
CIRT was estimated to be 3.0 at the distal portion of the
spread-out Bragg peak on the basis of previous studies.18
For treatment planning, the clinical target volume (CTV)
was determined by the combination of the structures of
the prostate and seminal vesicle (SV). For T1c to T3a dis-
ease, the CTV was contoured from the root to the proxi-
mal third or half of the SV, and for T3b disease, the CTV
included the SV in its entirety as much as possible. Plan-
ning target volume 1 was determined by the addition of 5-
mm margins in the cranial, caudal, and posterior direc-
tions and 10-mm margins in the right, left, and anterior
directions. Planning target volume 2, used as a boost ther-
apy to reduce the dose to the organs at risk from half of
the treatment course, was created by the addition of 2- to
3-mmmargins from the dorsal aspect of the CTV and was
identical to the CTV in the cranial and caudal directions.
CIRT was performed once a day 4 days a week. One
port was used per session. In the 2 protocols of this study,
3 radiation ports were used in the bilateral and anterior
directions. The bladder was filled with 100 mL of steri-
lized water for CT planning and at each treatment session
for the anterior direction. Alignments were determined
only for the skeletal anatomy via the overlapping of the
deviation between the onboard image and the digitally
reconstructed radiograph, which was created during CT
treatment planning.
The follow-up duration interval was defined as the
time from the date of CIRT initiation to the date of the
last follow-up. Clinical records were collected in April
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2015. The primary endpoint of this study was OAM,
which was measured from the date of CIRT initiation to
the date of death. PCSM was measured from the date of
CIRT initiation to the date of death due to prostate can-
cer. BR was defined as the PSA nadir plus 2.0 ng/mL (the
Phoenix definition).5
The OAM rates and comparisons between patients
with BR and patients without BR, adjusted for the ADT
duration, were calculated with a Cox proportional hazards
model.23 The PCSM rates, with non–prostate cancer
mortality (NPCM) accounted for as a competing risk for
PCSM, and comparisons between patients with BR and
patients without BR were calculated with Gray’s test.24 As
for the relation between predictive factors and mortality, a
Cox proportional hazards model23 was used for OAM,
and the method of Fine and Gray25 was used for PCSM;
it accounted for NPCM as a competing risk in the univar-
iate analysis. Multivariate analyses using the forced entry
method were performed for OAM according to a Cox
proportional hazards model with BR as a time-dependent
covariate26 and for PCSM with NPCM accounted for as a
competing risk according to the method of Fine and
Gray.25 The Mann-Whitney test was used for a compari-
son of the median follow-up and the ADT duration. The
chi-square test was used for a comparison of the propor-
tion of patients. Differences were considered significant if
the P value was <.05. We used EZR (version 1.32)27 to
perform Gray’s test24 and the method of Fine and Gray
for competing risks.25 All other calculations were per-
formed with the IMB SPSS statistical computer program
(version 22; IBM Japan, Ltd, Tokyo, Japan).
Patients were followed up at 3-month intervals dur-
ing the first 5 years after CIRT and at 3- to 6-month inter-
vals thereafter.
RESULTS
Patient Characteristics and Outcomes
Of the 466 patients, 324 who were considered to have
high-risk prostate cancer and who had been followed up
for at least 12 months were evaluated in the current study.
The median follow-up interval was 107.4 months (range,
13.3-167.7 months), and the median ADT duration was
30.2 months (range, 3.9-159.3 months). Table 1 shows
the background characteristics of the patients.
By the time of the last follow-up, BR, OAM, and
PCSM were observed in 60 (18.5%), 72 (22.2%), and 15
patients (4.6%), respectively. The 5- and 10-year rates for
the evaluated patients were 7.0% (95% confidence inter-
val [CI], 4.0%-9.4%) and 23.9% (95% CI, 16.4%-
26.2%), respectively, for OAM (adjusted for the ADT du-
ration) and 2.2% (95% CI, 1.0%-4.2%) and 4.6% (95%
CI, 2.6%-7.4%), respectively, for PCSM (with NPCM
accounted for as a competing risk).
Relation Between BR and Mortality
Among the 60 patients with BR, there were 14 PCSM
events (23.3%) and 7 NPCM events (11.7%). Among the
264 patients without BR, there were 1 PCSM event
(0.4%) and 50 NPCM events (18.9%). The 1 PCSM-
without-BR case had received 66 Gy (RBE) over 20 frac-
tions, and 4 months after CIRT, inguinal and para-aortic
lymph node swelling was detected without a PSA eleva-
tion. He died 13 months after CIRT. There were 57
NPCM events in all, and cardiovascular related mortality
was observed in 4 of these patients (myocardial infarction
in 2 and brain infarction in 2).
The 5- and 10-year OAM rates, adjusted for the
ADT duration, for the BR patients were 11.7% (95% CI,
3.5%-19.9%) and 31.9% (95% CI, 19.2%-44.6%),
respectively, but the corresponding rates for the non-BR
patients were 5.6% (95% CI, 2.9%-8.3%) and 18.8%
(95% CI, 13.5%-24.1%), respectively. Similarly, the 5-
and 10-year rates for PCSM, with NPCM accounted for
as a competing risk, were 10.0% (95% CI, 4.0%-19.2%)
and 23.0% (95% CI, 12.8%-34.9%), respectively, for the
BR patients and 0.4% (95% CI, 0.0%-2.0%) and 0.4%
TABLE 1. Patient, Tumor, and Treatment Character-
istics (n 5 324)
Follow-up time, median (range), mo 107.4 (13.3–167.7)
Age, median (range), y 69 (51–92)
T stage, No. (%)
T1c-T2b 78 (24)
T2c 88 (27)
T3a/b 158 (49)
PSA, No. (%)
10 ng/mL 68 (21)
>10, 20 ng/mL 82 (25)
>20 ng/mL 174 (54)
Gleason score, No. (%)
6 42 (13)
7 146 (45)
8 58 (18)
9 or 10 78 (24)
Duration of ADT, No. (%)
<12 mo 29 (9)
12, <24 mo 71 (22)
24 mo 224 (69)
Prescribed dose, No. (%)
66 Gy (RBE)/20 fractions 174 (54)
63 Gy (RBE)/20 fractions 150 (46)
Abbreviations: ADT, androgen-deprivation therapy; PSA, prostate-specific
antigen; RBE, relative biological effect.
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(95% CI, 0.0%-2.0%), respectively, for the non-BR
patients.
Univariate analyses revealed that BR, age, T stage,
PSA level, and GS had significant impacts on OAM and
PCSM, respectively (Table 2), whereas the multivariate
analysis determined that BR (hazard ratio [HR], 2.82;
95% CI, 1.57-5.08; P 5 .001), an age  70 years (HR,
3.05; 95% CI, 1.84-5.08; P < .001), and T3a/b disease
(HR, 1.74; 95% CI, 1.03-2.92; P5 .037) had significant
impacts on OAM (Table 3). Moreover, only BR had a sig-
nificant impact on PCSM, with NPCM accounted for as
a competing risk, in the multivariate analysis (HR, 38.19;
95% CI, 4.78-305.30; P < .001; Table 3). On the other
hand, there was no significant difference in the median
follow-up or ADT duration between BR and non-BR
patients. In addition, the proportion of patients  70
years old in the BR group was significantly lower than
that in the non-BR group (28% [17 of 60] vs 53% [139 of
264]; P5 .001).
DISCUSSION
Long-term follow-up results from 2 prospective studies of
CIRT involving 324 high-risk prostate cancer patients at
the NIRS showed that the 10-year rates of OAM, adjusted
for ADT duration, and PCSM, with NPCM accounted
for as a competing risk, were 23.9% and 4.6%, respec-
tively. These favorable outcomes for patients with high-
risk prostate cancer may be due to various reasons. The
high radiation doses used in the clinical trials might have
contributed to the high tumor control rate; the total doses
of 66 and 63 Gy in 20 fractions correspond to 90.5 and
82.9 Gy in a 2-Gy fraction, respectively, when the linear-
quadratic model with a/b5 1.5 Gy is applied.28 A meta-
analysis of multiple randomized studies indicated that
high-dose RT yielded better BR-free rates than
conventional-dose RT in low- to high-risk prostate cancer
patients.29 Furthermore, Kalbasi et al30 reported that dose
escalation improves overall survival in patients with inter-
mediate- and high-risk disease. On the other hand, there
was no significant difference in the effect on OAM
between 66 and 63 Gy (RBE) in the current study. Fur-
thermore, the high RBE of carbon ions might lead to a
high tumor control rate in prostate cancer, which is a
slow-growing tumor.
BR has been used as an indicator of early-stage recur-
rence in follow-up examinations after RT as well as
TABLE 2. Univariate Analysis of OAM and PCSM Accounting for NPCM as a Competing Risk in Patients
With Modified D’Amico High-Risk Prostate Cancer Treated With Carbon-Ion Radiotherapy
Factor OAM Rate
OAM
PCSM With Competing Event
of NPCM
Cox Regression Model23 Fine and Gray Model25
HR 95% CI P HR 95% CI P
BR, positive vs negative 35% (21/60) vs 19% (51/264) 1.77 1.07–2.95 .028 66.11 8.59–508.60 <.001
Age vs
65 vs <65 y 26% (64/250) vs 11% (8/74) 2.52 1.21–5.27 .014 0.57 0.19–1.67 .310
70 vs <70 y 31% (49/156) vs 14% (23/168) 2.60 1.58–4.26 <.001 0.53 0.18–1.56 .250
75 vs <75 y 32% (19/59) vs 20% (53/265) 1.93 1.14–3.27 .014 0.72 0.16–3.21 .660
80 vs <80 y 50% (3/6) vs 22% (69/318) 5.76 1.79–18.54 .003 5.64 0.65–48.77 .120
T stage vs
T2c vs T2b 24% (59/246) vs 17% (13/78) 1.44 0.79–2.62 .236 NA —
T3a/b vs T2c 29% (46/158) vs 17% (26/166) 1.82 1.13–2.96 .015 14.65 1.94–110.70 .009
PSA vs
>20 vs 20 ng/mL 28% (50/176) vs 15% (22/148) 1.85 1.12–3.06 .017 3.26 0.92–11.50 .066
>30 vs 30 ng/mL 28% (32/114) vs 19% (40/210) 1.38 0.87–2.21 .174 5.01 1.61–15.56 .005
>40 vs 40 ng/mL 31% (26/85) vs 19% (46/239) 1.50 0.92–2.43 .103 5.59 1.93–16.16 .002
>50 vs 50 ng/mL 30% (19/64) vs 20% (53/260) 1.41 0.83–2.39 .200 3.54 1.27–9.85 .015
Gleason score vs
7 vs 6 22% (61/282) vs 26% (11/42) 0.93 0.49–1.77 .830 NA —
8 vs 7 24% (33/136) vs 21% (39/188) 1.42 0.89–2.26 .144 1.73 0.64–4.73 .280
9 or 10 vs 8 28% (22/78) vs 20% (50/246) 1.67 1.01–2.76 .047 3.98 1.45–10.83 .007
Duration of ADT vs
12 vs <12 mo 22% (64/295) vs 28% (8/29) 0.64 0.31–1.34 .230 1.31 0.19–9.10 .780
24 vs <24 mo 21% (46/224) vs 26% (26/100) 0.86 0.53–1.39 .539 0.69 0.25–1.89 .480
Dose, 66 vs 63 Gy (RBE) 29% (51/174) vs 14% (21/150) 1.32 0.77–2.27 .312 1.44 0.49–4.23 .510
Abbreviations: ADT, androgen-deprivation therapy; BR, biochemical recurrence; CI, confidence interval; HR, hazard ratio; NA, not available; NPCM, non–pros-
tate cancer mortality; OAM, overall mortality; PCSM, prostate cancer–specific mortality; PSA, prostate-specific antigen; RBE, relative biological effect.
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surgery. However, few previous studies have shown a posi-
tive relation between BR itself and patient mortal-
ity.7,8,11,31 Kapadia et al11 reported the clinical outcomes
of 710 patients with low- to high-risk prostate cancer who
received high-dose RT (median, 78 Gy). In their study,
79% of 231 high-risk patients received RT combined
with long-term ADT (median duration, 21 months), and
37% of the 231 patients experienced BR, which was
defined according to the Phoenix definition. Although
the BR rate in their study was higher than that in the cur-
rent study (18.5% or 60 of 324 patients), the treatments,
in terms of a high radiation dose and long-term ADT,
were similar between the 2 studies. As a result, the rate of
PCSM for high-risk patients with BR was significantly
higher than the rate for those without BR, although the
impact of BR on OAM could not be demonstrated in
their study. The multivariate analysis in this study, taking
into consideration the competing risk of NPCM, also
revealed a significant relation between BR and PCSM.
These results suggest that BR itself could be a predictive
factor for PCSM in patients treated with high-dose RT
combined with long-term ADT.
On the other hand, at least 2 previous studies have
demonstrated a significant impact of BR on OAM,7,8 but
in one of the studies, the patients underwent surgery.7
The other study, reported by Abramowitz et al,8 was the
first to indicate a relation between BR, as determined by
the Phoenix criteria, and OAM in a series combining RT
with ADT; their results could support those of the current
study. However, the backgrounds of our study and their
study were slightly different; for example, in their study,
ADT was used for a relatively short-term period (median,
7.7 months) and was administered to a limited number of
patients (16%).8
Because the addition of ADT (particularly long-
term ADT) to definitive RT decreases the OAM of high-
risk prostate cancer patients,32,33 the differences in the
time to mortality between patients with and without BR
tend to be small, and all patients in the current study
received ADT over a median duration of 30.2 months.
Nevertheless, BR was an independent predictive factor for
OAM in the multivariate analysis, and there was no differ-
ence in either the follow-up time or the ADT duration
between the BR patients and the non-BR patients. Sur-
prisingly, the proportion of patients  70 years old in the
BR group was significantly lower than that in the non-BR
group in the current study, although the elderly patients
had a significantly higher mortality risk than the younger
patients (<70 years) in the multivariate analysis, as would
be expected naturally. These results might have been at-
tributable to the PCSM rate being markedly higher in the
BR group (23.3%) than the non-BR group (0.3%),
whereas the rate of NPCM was lower in the BR group
(11.7%) than the non-BR group (18.9%). Thus, both
this study and the study by Abramowitz et al8 indicate
that BR has a significant impact on OAM. To the best of
our knowledge, this study provides a novel insight regard-
ing a significant relation between BR and OAM for high-
risk prostate cancer patients treated with high-dose parti-
cle beam therapy combined with long-term ADT.
There were several limitations to this study. First,
the data were collected from 2 prospective trials, but the
current study was a retrospective analysis. Therefore, there
may have been some bias associated with the secondary
analysis. Second, the timing of salvage therapy after BR
was heterogeneous, even though most of the BR patients
received ADT. Moreover, the treatments for castration-
resistant prostate cancer were not unified. Third, one
TABLE 3. Multivariate Analysis of OAM and PCSM Accounting for NPCM as a Competing Risk in Patients
With Modified D’Amico High-Risk Prostate Cancer Treated With Carbon-Ion Radiotherapy
Factor
OAM PCSM With Competing Event of NPCM
Cox Regression Model23 Fine and Gray Model25
HR 95% CI P HR 95% CI P
Biochemical recurrence 2.82 1.57–5.08 .001 38.19 4.78–305.30 <.001
Age  70 y 3.05 1.84–5.08 <.001 1.26 0.40–3.99 .700
T3a/b 1.74 1.03–2.92 .037 6.92 0.83–57.48 .073
PSA > 20 ng/mL 1.51 0.88–2.57 .134 1.85 0.37–9.27 .450
Gleason score of 9 or 10 1.34 0.76–2.36 .320 1.70 0.55–5.29 .360
Duration of ADT  24 mo 0.70 0.41–1.19 .189 0.36 0.10–1.33 .130
Dose of 66 Gy (RBE) 1.02 0.58–1.79 .952 1.01 0.32–3.20 .990
Abbreviations: ADT, androgen-deprivation therapy; CI, confidence interval; HR, hazard ratio; NA, not available; NPCM, non–prostate cancer mortality; OAM,
overall mortality; PCSM, prostate cancer–specific mortality; PSA, prostate-specific antigen; RBE, relative biological effect.
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complication of this method lies in the long lifespan of
the treated Japanese population, which may have affected
the results of this study. Fourth, the ADT duration for the
evaluated high-risk patients was not fixed because
T2cN0M0 patients with a PSA level  20 ng/mL and a
GS  7 received adjuvant ADT for 6 months or less,
whereas the other patients received adjuvant ADT for a
longer duration. In addition, multi-institutional long-
term survival data for a large number of patients are desir-
able for this kind of study, although data obtained from
more than 324 patients over a median follow-up of 107.4
months were evaluated in the current study. Hence, all 5
Japanese CIRT institutes will start planning multi-
institutional, prospective studies of treatments for high-
risk prostate cancer.
In conclusion, the combination of CIRT and ADT,
administered to patients with high-risk prostate cancer,
indicated a favorable prognosis, and this suggests that BR
is an independent predictive factor for OAM. In the near
future, prospective trials are needed to confirm these
results.
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